Guideline/Drug Updates and Errata

RxPrep content (e.g., NAPLEX® Course Book, MPJE®/CPJE Manuals and QBanks) is up-to-date at the time of publishing, but drug information and laws can change at any time. If information changes after a product is published, we will post exam-relevant updates in the Guideline/Drug Updates tables below. If we find anything that needs a correction or clarification, it will be included in the Errata tables below.

NAPLEX

MPJE

CPJE

NAPLEX

2024 2023

Updates: 2023 UWorld RxPrep Course Book

NAPLEX-relevant guideline and drug updates from June 2022-May 2023

Page	Update Type	Description
Chapters 15-17: Compounding I, II, and III
p. 226-281	Guideline Update	Revised United States Pharmacopeia (USP) chapters 795 (Nonsterile Preparations) and 797 (Sterile Preparations) were published on November 1, 2022, and the changes will become official on November 1, 2023. Since the changes will not be official until November 1, 2023, these updates are unlikely to have an immediate impact on the compounding content tested on the NAPLEX. USP 795 USP 797
Chapter 31: Chronic Heart Failure and Chapter 44: Diabetes
p. 466-469, 471	Guideline Update	The American Heart Association (AHA) and American College of Cardiology (ACC) released the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and aldosterone receptor antagonists are now considered initial medications for all patients with heart failure with reduced ejection fraction (HFrEF) without contraindications. 2022 AHA/ACC Heart Failure Guidelines
Chapter 42: Chronic Obstructive Pulmonary Disease
p. 590-591	Guideline Update	The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released the 2023 guidelines for COPD diagnosis, management, and prevention. Key changes that could impact testing include: The combined assessment of COPD has been changed from an ABCD system to an ABE system, where the previous groups of C and D are combined into one new group (E). Any patient with elevated risk of exacerbations is included in group E. The recommendations for initial pharmacologic therapy have been modified to match the new ABE system. Initial treatment by group includes: Group A: a bronchodilator (SABA PRN, SAMA PRN, LABA or LAMA) Group B: dual therapy (LABA + LAMA) Group E: dual therapy (LABA + LAMA) or triple therapy (LABA + LAMA + ICS) if blood eosinophils are ≥ 300 µ/L The exacerbation pathway of the Escalation of Treatment algorithm has changed. If a patient has high eosinophils (≥ 300 µ/L), escalate to triple therapy (LABA + LAMA + ICS). Dual therapy with LABA + ICS is no longer recommended. If eosinophils are < 300 µ/L, escalate to dual bronchodilator therapy (LABA + LAMA). If further escalation is needed for patients on dual bronchodilator therapy, an ICS can be considered if eosinophils are ≥ 100 µ/L. There continues to be no role (no proven benefit) of ICS if eosinophils are < 100 µ/L. Adding on roflumilast or azithromycin can still be considered as a final step, regardless of eosinophil counts. 2023 GOLD COPD Guidelines
Chapter 44: Diabetes
p. 607-608	Guideline Update	The 2023 American Diabetes Association (ADA) Standards of Care update was published. Key changes that could impact testing include: p. 607: Comprehensive Care, section on Cholesterol Control Goal LDL targets are now: < 55 mg/dL for patients with ASCVD. < 70 mg/dL for patients with high ASCVD risk. If these goals are not met with a high-intensity statin (or maximally tolerated dose), add-on agents (ezetimibe or PCSK9 inhibitor) are recommended. p. 607: Comprehensive Care, section on Diabetic Kidney Disease SGLT2 inhibitors are now recommended in patients with an eGFR ≥ 20 mL/min/1.73 m² to reduce CKD progression and cardiovascular events. Finerenone is recommended in patients with CKD + albuminuria (in addition to maximum tolerated doses of an ACE inhibitor or ARB and an SGLT2 inhibitor). p. 607: Comprehensive Care, section on Blood Pressure Control Goal blood pressure is now < 130/80 mmHg for all patients. p. 608: Treatment for Type 2 Diabetes and Treatment Algorithm GLP-1 agonists and SGLT2 inhibitors are first-line for cardiorenal comorbidities, with or without metformin (i.e., metformin does not need to be the first drug selected). Tirzepatide (Mounjaro), a GLP-1/GIP agonst, was added as a treatment option. It has high efficacy for both glycemic control and weight loss. 2023 ADA Guidelines

Errata: 2023 UWorld RxPrep Course Book

Corrections or clarifications for the 2023 RxPrep Course Book

Page	Description
Chapter 27: Dyslipidemia
p. 426	In the Statin Treatment Intensity Definitions and Selection Options table, pitavastain doses of 1-4 mg are considered moderate intensity.

Updates: 2024 UWorld RxPrep Course Book

NAPLEX-relevant guideline and drug updates from June 2023 – May 2024

Page

Update Type

Description

Chapter 15: Compounding I

p. 227, 237

Guideline Update

Revised United States Pharmacopeia (USP) chapters 795 (Non-sterile Preparations) and 797 (Sterile Preparations) became official on November 1, 2023.

The updates most relevant for testing that impact this chapter include:

p. 227: Non-Sterile Compounding

The categories of non-sterile compounding based on complexity (i.e., simple, moderate, complex) have been removed.

p. 237: Compounding Staff Training

For sterile compounding training, the gloved fingertip test and media fill test are now required every 6 months for compounders that are making only Category 1 and 2 sterile products (see updates for Compounding III chapter below).

USP 795

USP 797

Chapter 17: Compounding III

p. 266, 273, 277-278

Guideline Update

Revised USP chapters 795 and 797 became official on November 1, 2023. Key updates that impact this chapter include:

p. 273: Selecting the Beyond-Use Date for Non-Sterile Preparations

Beyond-use dates (BUDs) for non-sterile preparations have been revised and are now based on “water activity” (Aw), which refers to the available water in a compound for microbial growth and hydrolysis reactions. Aw would likely be provided on the exam.

Revised BUDs for Non-sterile Compounds

Aqueous dosage forms (Aw ≥ 0.60)

Nonpreserved = 14 days, store in refrigerator
Preserved = 35 days

Nonaqueous dosage forms (Aw < 0.60)

Oral liquids = 90 days
Other = 180 days

p. 277: Sterile Preparation and Risk

Risk categories for sterile preparations have been revised (see table below). Immediate-use has the highest risk of contamination and category 3 has the lowest.

Revised Risk Categories for Sterile Preparations
Risk Category	Environment for Preparation
Immediate-use	Uncontrolled [no primary engineering control (PEC)]
Category 1	ISO 5 PEC in a segregated compounding area (SCA)
Category 2	ISO 5 PEC in a cleanroom
Category 3	ISO 5 PEC in a cleanroom with additional requirements

p. 278: Determining the Beyond-Use Date Based on CSP Risk Level

BUD limits for sterile preparations have been revised and are now based on preparation conditions (e.g., aseptic preparation versus terminal sterilization), sterility testing, and other criteria.

Revised BUD Limits for Sterile Preparations
Category	Room Temp	Refrigerated	Frozen
Immediate-use	4 hours
1	12 hours	24 hours	N/A
2	1-45 days	4-60 days	45-90 days
3	60-90 days	90-120 days	120-180 days

USP 795

USP 797

Chapter 20: Immunizations

p. 313, 318

Guideline Update

The Advisory Committee on Immunization Practices (ACIP) updated their recommendations for influenza vaccine administration in patients with an egg allergy (of any severity). The requirement to administer select vaccines (i.e., those that are not egg-free) in a medical setting under the supervision of a healthcare provider has been removed. No additional safety precautions are required, although providers should always be prepared for emergent situations with any vaccine administration.

2023-2024 ACIP Flu

p. 314, 320

Guideline Update

The Centers for Disease Control (CDC) released the 2024 Immunization Schedules for Children and Adolescents and Adults.

The updates most relevant for testing that impact this chapter include:

p. 314: New respiratory syncytial virus (RSV) vaccine and antibody recommendations for select populations

Pregnancy: pregnant people 32-36 weeks gestation during RSV season should receive 1 dose of the RSV vaccine (Abrysvo only) to protect the infant.
Infants and children: infants age < 8 months during their first RSV season should receive 1 dose of nirsevimab (Beyfortus) (RSV monoclonal antibody) if RSV vaccination was not administered during pregnancy.
Older adults: patients age ≥ 60 years at increased risk can receive (per shared clinical decision making) 1 dose of an RSV vaccine (Abrysvo or Arexvy).

p. 320: Pneumococcal vaccines

Children age < 5 years: PCV15 or PCV20 is recommended for routine vaccination (PCV13 has been removed from all schedules).

2024 Immunization Schedules

Chapter 44: Diabetes

p. 600-601

Guideline Update

The 2024 American Diabetes Association (ADA) Standards of Care update was published. There were no significant changes that impacted the 2024 UWorld RxPrep course book content.

2024 ADA Guidelines

Chapter 47: Contraception & Infertility

p. 652–654

New Drug

The FDA has approved norgestrel 0.075 mg (Opill) as the first nonprescription (OTC) oral contraceptive. Opill is a progestin-only pill that should be taken once daily at the same time every day.

2024 2023

Updates: 2023 UWorld RxPrep Course Book

NAPLEX-relevant guideline and drug updates from June 2022-May 2023

Chapters 15-17: Compounding I, II, and III
Page p. 226-281	Update type Guideline Update
Revised United States Pharmacopeia (USP) chapters 795 (Nonsterile Preparations) and 797 (Sterile Preparations) were published on November 1, 2022, and the changes will become official on November 1, 2023. Since the changes will not be official until November 1, 2023, these updates are unlikely to have an immediate impact on the compounding content tested on the NAPLEX. USP 795 USP 797
Chapter 31: Chronic Heart Failure and Chapter 44: Diabetes
Page p. 466-469, 471	Update type Guideline Update
The American Heart Association (AHA) and American College of Cardiology (ACC) released the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and aldosterone receptor antagonists are now considered initial medications for all patients with heart failure with reduced ejection fraction (HFrEF) without contraindications. 2022 AHA/ACC Heart Failure Guidelines
Chapter 42: Chronic Obstructive Pulmonary Disease
Page p. 590-591	Update type Guideline Update
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released the 2023 guidelines for COPD diagnosis, management, and prevention. Key changes that could impact testing include: The combined assessment of COPD has been changed from an ABCD system to an ABE system, where the previous groups of C and D are combined into one new group (E). Any patient with elevated risk of exacerbations is included in group E. The recommendations for initial pharmacologic therapy have been modified to match the new ABE system. Initial treatment by group includes: Group A: a bronchodilator (SABA PRN, SAMA PRN, LABA or LAMA) Group B: dual therapy (LABA + LAMA) Group E: dual therapy (LABA + LAMA) or triple therapy (LABA + LAMA + ICS) if blood eosinophils are ≥ 300 µ/L The exacerbation pathway of the Escalation of Treatment algorithm has changed. If a patient has high eosinophils (≥ 300 µ/L), escalate to triple therapy (LABA + LAMA + ICS). Dual therapy with LABA + ICS is no longer recommended. If eosinophils are < 300 µ/L, escalate to dual bronchodilator therapy (LABA + LAMA). If further escalation is needed for patients on dual bronchodilator therapy, an ICS can be considered if eosinophils are ≥ 100 µ/L. There continues to be no role (no proven benefit) of ICS if eosinophils are < 100 µ/L. Adding on roflumilast or azithromycin can still be considered as a final step, regardless of eosinophil counts. 2023 GOLD COPD Guidelines
Chapter 44: Diabetes
Page p. 607-608	Update type Guideline Update
The 2023 American Diabetes Association (ADA) Standards of Care update was published. Key changes that could impact testing include: p. 607: Comprehensive Care, section on Cholesterol Control Goal LDL targets are now: < 55 mg/dL for patients with ASCVD. < 70 mg/dL for patients with high ASCVD risk. If these goals are not met with a high-intensity statin (or maximally tolerated dose), add-on agents (ezetimibe or PCSK9 inhibitor) are recommended. p. 607: Comprehensive Care, section on Diabetic Kidney Disease SGLT2 inhibitors are now recommended in patients with an eGFR ≥ 20 mL/min/1.73 m2 to reduce CKD progression and cardiovascular events. Finerenone is recommended in patients with CKD + albuminuria (in addition to maximum tolerated doses of an ACE inhibitor or ARB and an SGLT2 inhibitor). p. 607: Comprehensive Care, section on Blood Pressure Control Goal blood pressure is now < 130/80 mmHg for all patients. p. 608: Treatment for Type 2 Diabetes and Treatment Algorithm GLP-1 agonists and SGLT2 inhibitors are first-line for cardiorenal comorbidities, with or without metformin (i.e., metformin does not need to be the first drug selected). Tirzepatide (Mounjaro), a GLP-1/GIP agonst, was added as a treatment option. It has high efficacy for both glycemic control and weight loss. 2023 ADA Guidelines

Errata: 2023 UWorld RxPrep Course Book

Corrections or clarifications for the 2023 RxPrep Course Book

Chapter 27: Dyslipidemia
Page p. 426
In the Statin Treatment Intensity Definitions and Selection Options table, pitavastain doses of 1-4 mg are considered moderate intensity.

Updates: 2024 UWorld RxPrep Course Book

NAPLEX-relevant guideline and drug updates from June 2023 – May 2024

Chapter 15: Compounding I

Page
p. 227, 237

Update Type
Guideline Update

Revised United States Pharmacopeia (USP) chapters 795 (Non-sterile Preparations) and 797 (Sterile Preparations) became official on November 1, 2023.

The updates most relevant for testing that impact this chapter include:

p. 227: Non-Sterile Compounding

The categories of non-sterile compounding based on complexity (i.e., simple, moderate, complex) have been removed.

p. 237: Compounding Staff Training

For sterile compounding training, the gloved fingertip test and media fill test are now required every 6 months for compounders that are making only Category 1 and 2 sterile products (see updates for Compounding III chapter below).

USP 795

USP 797

Chapter 17: Compounding III

Page
p. 266, 273, 277-278

Update Type
Guideline Update

Revised USP chapters 795 and 797 became official on November 1, 2023. Key updates that impact this chapter include:

p. 273: Selecting the Beyond-Use Date for Non-Sterile Preparations

Beyond-use dates (BUDs) for non-sterile preparations have been revised and are now based on “water activity” (Aw), which refers to the available water in a compound for microbial growth and hydrolysis reactions. Aw would likely be provided on the exam.

Revised BUDs for Non-sterile Compounds

Aqueous dosage forms (Aw ≥ 0.60)

Nonpreserved = 14 days, store in refrigerator
Preserved = 35 days

Nonaqueous dosage forms (Aw < 0.60)

Oral liquids = 90 days
Other = 180 days

p. 277: Sterile Preparation and Risk

Risk categories for sterile preparations have been revised (see table below). Immediate-use has the highest risk of contamination and category 3 has the lowest.

Revised Risk Categories for Sterile Preparations
Risk Category	Environment for Preparation
Immediate-use	Uncontrolled [no primary engineering control (PEC)]
Category 1	ISO 5 PEC in a segregated compounding area (SCA)
Category 2	ISO 5 PEC in a cleanroom
Category 3	ISO 5 PEC in a cleanroom with additional requirements

p. 278: Determining the Beyond-Use Date Based on CSP Risk Level

BUD limits for sterile preparations have been revised and are now based on preparation conditions (e.g., aseptic preparation versus terminal sterilization), sterility testing, and other criteria.

Revised BUD Limits for Sterile Preparations
Category	Room Temp	Refrigerated	Frozen
Immediate-use	4 hours
1	12 hours	24 hours	N/A
2	1-45 days	4-60 days	45-90 days
3	60-90 days	90-120 days	120-180 days

USP 795

USP 797

Chapter 20: Immunizations

Page
p. 313, 318

Update Type
Guideline Update

2023-2024 ACIP Flu

p. 314, 320

Guideline Update

The Centers for Disease Control (CDC) released the 2024 Immunization Schedules for Children and Adolescents and Adults.

The updates most relevant for testing that impact this chapter include:

p. 314: New respiratory syncytial virus (RSV) vaccine and antibody recommendations for select populations

Pregnancy: pregnant people 32-36 weeks gestation during RSV season should receive 1 dose of the RSV vaccine (Abrysvo only) to protect the infant.
Infants and children: infants age < 8 months during their first RSV season should receive 1 dose of nirsevimab (Beyfortus) (RSV monoclonal antibody) if RSV vaccination was not administered during pregnancy.
Older adults: patients age ≥ 60 years at increased risk can receive (per shared clinical decision making) 1 dose of an RSV vaccine (Abrysvo or Arexvy).

p. 320: Pneumococcal vaccines

Children age < 5 years: PCV15 or PCV20 is recommended for routine vaccination (PCV13 has been removed from all schedules).

2024 Immunization Schedules

Chapter 44: Diabetes

Page
p. 600-601

Update Type
Guideline Update

The 2024 American Diabetes Association (ADA) Standards of Care update was published. There were no significant changes that impacted the 2024 UWorld RxPrep course book content.

2024 ADA Guidelines

Chapter 47: Contraception & Infertility

Page
p. 652–654

Update Type
New Drug

The FDA has approved norgestrel 0.075 mg (Opill) as the first nonprescription (OTC) oral contraceptive. Opill is a progestin-only pill that should be taken once daily at the same time every day.

MPJE

MPJE Updates: 7th Edition Federal Law Summary for MPJE

MPJE-relevant updates from January 2021-Present

Page

Update Type

Description

Chapter 1: Preparing for the MPJE with RxPrep

p. 3-4

Revised NABP MPJE Competency Statements

Effective October 2023

NABP has released revised MPJE Competency Statements (their blueprint of tested items).

Impact for MPJE Candidates testing October 2023 or later:

The 2023 MPJE Competency Statements have been reorganized across more “Areas.”
The types of questions and general format of the exam (e.g., number of questions and time to take the test) is the same.
The must-know content has not changed. Continue to use the RxPrep MPJE Course materials for your MPJE preparation.

Comparison of previous and new MPJE Competency Areas:

Previous MPJE Competency Statement Areas, Prior to October 2023 (Three Areas)	New MPJE Competency Statement Areas, Starting October 2023 (Four Areas)
Area 1 (83%) Pharmacy Practice	Area 1 (22%) Licensure/Personnel
Area 2 (15%) Licensure, Registration, Certification and Operational Requirements	Area 2 (33%) Pharmacist Practice
Area 3 (2%) General Regulatory Processes	Area 3 (24%) Dispensing Requirements
	Area 4 (21%) Pharmacy Operations

Exam content will be distributed more evenly between the new Competency Areas. While the previous Area 3 of “General Regulatory Process” is not included in the new statements, the application of the material is likely still testable. For example:

The previous Area 3 competency statement (3.1) focused on knowing specific laws and rules like the Food, Drug, and Cosmetic Act.
The new Area 3 competency statement (3.7) “drug product conditions prohibiting dispensing” may refer to misbranding and adulteration, which arose out of the Food, Drug, and Cosmetic Act.

New MPJE Competency Statements (Starting October 2023)

Chapter 3: Pharmacy Operations

p. 44

DEA Update

Effective October 2020

All controlled substances (schedule II – V) can be stored in a locked cabinet or dispersed among other drugs. Prior to this change, schedule II drugs needed to be stored in a securely locked cabinet or vault and could not be dispersed throughout the stock of non-controlled drugs.
2020 DEA Pharmacist’s Manual

Chapter 4: Pharmacy Practice

p. 77

Interchangeable Biosimilar Approval

Effective July 2021

The following update impacts the last sentence in the section under Biologics and Biosimilars.

The FDA approved two interchangeable biosimilar products in 2021. The following are interchangeable:

Insulin glargine-ygfn (Semglee) for insulin glargine (Lantus)
Adalimumab-adbm (Cyltezo) for adalimumab (Humira)

Chapter 8: Controlled Substance Part 3: Prescribing and Dispensing

p. 137, 154 -155

Law Update

Effective June 2023

The following update impacts these sections:

P. 137, second paragraph regarding the DATA 2000 waiver unique identification number
P. 154-155, the section on Opioid Dependence Treatment in an Office-Based Setting

On December 29, 2022, Congress eliminated the “DATA-Waiver Program” in order to increase access to buprenorphine and introduced new training requirements for all prescribers.

A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
All prescriptions for buprenorphine now require only a standard DEA registration number (previous “X” in DEA number is no longer required).
There are no longer any limits on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
The Act does not impact existing state laws that may be applicable.

DEA Informational Document

Chapter 1: Preparing for the MPJE with RxPrep

Page
p. 3-4

Update type
Revised NABP MPJE Competency Statements
Effective October 2023

NABP has released revised MPJE Competency Statements (their blueprint of tested items).

Impact for MPJE Candidates testing October 2023 or later:

The 2023 MPJE Competency Statements have been reorganized across more “Areas.”
The types of questions and general format of the exam (e.g., number of questions and time to take the test) is the same.
The must-know content has not changed. Continue to use the RxPrep MPJE Course materials for your MPJE preparation.

Comparison of previous and new MPJE Competency Areas:

Previous MPJE Competency Statement Areas, Prior to October 2023 (Three Areas)	New MPJE Competency Statement Areas, Starting October 2023 (Four Areas)
Area 1 (83%) Pharmacy Practice	Area 1 (22%) Licensure/Personnel
Area 2 (15%) Licensure, Registration, Certification and Operational Requirements	Area 2 (33%) Pharmacist Practice
Area 3 (2%) General Regulatory Processes	Area 3 (24%) Dispensing Requirements
	Area 4 (21%) Pharmacy Operations

The previous Area 3 competency statement (3.1) focused on knowing specific laws and rules like the Food, Drug, and Cosmetic Act.
The new Area 3 competency statement (3.7) “drug product conditions prohibiting dispensing” may refer to misbranding and adulteration, which arose out of the Food, Drug, and Cosmetic Act.

New MPJE Competency Statements (Starting October 2023)

Chapter 3: Pharmacy Operations

Page
p. 44

Update type
DEA Update
Effective October 2020

Chapter 4: Pharmacy Practice

Page
p. 77

Update type
Interchangeable Biosimilar Approval
Effective July 2021

The following update impacts the last sentence in the section under Biologics and Biosimilars.

The FDA has now approved interchangeable biosimilar products. For example, the following are deemed interchangeable:

Insulin glargine-ygfn (Semglee) for insulin glargine (Lantus)
Adalimumab-adbm (Cyltezo) for adalimumab (Humira)

Chapter 8: Controlled Substance Part 3: Prescribing and Dispensing

Page
p. 137, 154 -155

Law Update
Effective June 2023

The following update impacts these sections:

P. 137, second paragraph regarding the DATA 2000 waiver unique identification number
P. 154-155, the section on Opioid Dependence Treatment in an Office-Based Setting

On December 29, 2022, Congress eliminated the “DATA-Waiver Program” in order to increase access to buprenorphine and introduced new training requirements for all prescribers.

A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
All prescriptions for buprenorphine now require only a standard DEA registration number (previous “X” in DEA number is no longer required).
There are no longer any limits on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
The Act does not impact existing state laws that may be applicable.

DEA Informational Document

CPJE

CPJE Updates: 8th Edition California Law Summary for CPJE

CPJE-relevant updates from June 2023 – present

Page	Update Type	Description
Chapter 4: Pharmacy Practice Part 2: Furnishing, Administering and Clinical Services
p. 69	New Law Effective September 2023	A pharmacist can furnish oral drugs approved or authorized by the FDA for COVID-19 to a patient that has had a positive test for SARS-CoV-2. When furnishing, the pharmacist must: Use evidence-based clinical guidelines published by the FDA. Notify the patient’s primary care provider or enter the information in a shared patient record system. If the patient does not have a primary care provider, the pharmacist must provide the patient with a written record of what they received and advise the patient to consult a physician. Document the drug(s) and quantity furnished and any testing provided in the patient’s pharmacy record, and keep this documentation for 3 years. B&PC 4052.04
p. 74	New Drug Effective July 2023	The FDA has approved a new over-the-counter (OTC) naloxone product (brand name RiVive) indicated for the emergency treatment of known or suspected opioid overdose. RiVive will be available as a 3-milligram nasal spray.
p. 80-81	Law change Effective February 2024	The law for furnishing HIV pre-exposure prophylaxis (PrEP) has been updated as follows: Pharmacists are authorized to furnish up to a 90-day supply of approved medications to a single patient every two years (if eligibility criteria are met). A pharmacist may furnish subsequent 90-day courses of PrEP if the pharmacist ensures that the patient receives testing and follow-up care consistent with CDC guidelines, documents the services provided in the patient’s record and notifies the patient’s primary care provider that these requirements were completed. B&PC 4052.02

Chapter 4: Pharmacy Practice Part 2: Furnishing, Administering and Clinical Services
Page p. 69	New Law Effective September 2023
A pharmacist can furnish oral drugs approved or authorized by the FDA for COVID-19 to a patient that has had a positive test for SARS-CoV-2. When furnishing, the pharmacist must: Use evidence-based clinical guidelines published by the FDA. Notify the patient’s primary care provider or enter the information in a shared patient record system. If the patient does not have a primary care provider, the pharmacist must provide the patient with a written record of what they received and advise the patient to consult a physician. Document the drug(s) and quantity furnished and any testing provided in the patient’s pharmacy record, and keep this documentation for 3 years.
Page p. 74	New Drug Effective July 2023
The FDA has approved a new over-the-counter (OTC) naloxone product (brand name RiVive) indicated for the emergency treatment of known or suspected opioid overdose. RiVive will be available as a 3-milligram nasal spray.
Page p. 80-81	Law change Effective February 2024
The law for furnishing HIV pre-exposure prophylaxis (PrEP) has been updated as follows: Pharmacists are authorized to furnish up to a 90-day supply of approved medications to a single patient every two years (if eligibility criteria are met). A pharmacist may furnish subsequent 90-day courses of PrEP if the pharmacist ensures that the patient receives testing and follow-up care consistent with CDC guidelines, documents the services provided in the patient’s record and notifies the patient’s primary care provider that these requirements were completed. B&PC 4052.02

CPJE Errata: 8th Edition California Law Summary for CPJE

Corrections or clarifications for the 8th Edition UWorld RxPrep CPJE manual

Page	Description
Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing
p. 32	In the Optometrist (OD) row of the table, the right column should read: Must be certified by the Board of Optometry to prescribe drugs. These optometrists will have three letters starting with a T at the end of their license number. Independent authority: Non-controlled drugs (limited to scope of practice), with topical and oral antiglaucoma agents limited to patients ≥ 18 years old. 3-day supply of codeine combination products, hydrocodone combination products or tramadol. With additional training: can administer influenza, herpes zoster virus, pneumococcal and Covid-19 immunizations recommended by the CDC for patients ≥ 18 years. Dependent authority: Oral steroids in patients under 18 years old. Oral non-antibiotic drugs in patients < 5 years old. B&PC 3041
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing
p. 135	The first sentence of the second paragraph below the “Purchase Requirements for OTC Sales” section should read: Although the DEA requires that the logbook be kept in a secure location for at least two years, California law is more strict and requires records to be kept for at least three years. B&PC 4081

Chapter 3: Pharmacy Practice Part 1: Prescribing and Dispensing
Page p. 32
In the Optometrist (OD) row of the table, the right column should read: Must be certified by the Board of Optometry to prescribe drugs. These optometrists will have three letters starting with a T at the end of their license number. Independent authority: Non-controlled drugs (limited to scope of practice), with topical and oral antiglaucoma agents limited to patients ≥ 18 years old. 3-day supply of codeine combination products, hydrocodone combination products or tramadol. With additional training: can administer influenza, herpes zoster virus, pneumococcal and Covid-19 immunizations recommended by the CDC for patients ≥ 18 years. Dependent authority: Oral steroids in patients under 18 years old. Oral non-antibiotic drugs in patients < 5 years old. B&PC 3041
Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing
p. 135	The first sentence of the second paragraph below the “Purchase Requirements for OTC Sales” section should read: Although the DEA requires that the logbook be kept in a secure location for at least two years, California law is more strict and requires records to be kept for at least three years. B&PC 4081